InSysBio to present COVID-19 QSP model further development

NEWS
Publication
June 30, 2020

June 30, 2020

InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

Model description:

In addition to sub-model describing virus and pneumocyte life cycles InSysBio team has constructed a sub-model describing life cycle of macrophages. Now we present the scheme of the sub-model and quality of calibration against in vivo baseline data. The sub-model describes:

  • influx of monocytes (PBM) from bone marrow regulated by GMCSF,
  • PBM migration to lung tissue stimulated by CCL2, CXCL10 and TGFb,
  • PBM polarization to M1/M2 macrophages regulated by Antigen, IFNg, IL10, TGFb, IL4 and IL13,
  • IL1b, IL6, IL10, IL12, IL23, TNFa, TGFb, CXCL10 and CCL2 production by the PBM and macrophages,
  • cytokine/chemokine distribution between lung tissue, plasma and lymph node,
  • cytokine chemokine degradation.

The model is preliminary calibrated against available in vitro data describing regulatory effects of cytokines/chemokines on cell dynamics and then finally calibrated against in vivo baseline data measured for healthy subjects.
To learn more about the model and detailed description of calibration, please, visit: https://github.com/insysbio/covid19-qsp-model

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

September 2025
MoTuWeThFrSaSu
1
2
3
4
5
6
7
8
9
10
1. 10 Sep 2025 15:18 InSysBio to participate in ACoP 2025 InSysBio announces its participation in 2025 American Conference on Pharmacometrics (ACoP 2025) which is to be held from October 18-21, 2025 at the Gaylord Rockies, Aurora, Colorado, USA. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #11 and 2 posters in frames of the Conference
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
     
Upcoming Events
18.10
InSysBio to participate in ACoP 2025
Tags
Latest News
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling
25.06
InSysBio to announce extension of collaboration with discoveric bio alpha
18.06
InSysBio to publish the new article in CPT: Pharmacometrics & Systems Pharmacology
03.06
InSysBio to present Integration of Cytocon DB and fIVE DB with Heta for QSP modeling